|1.||Jones, Ronald N: 6 articles (05/2007 - 05/2002)|
|2.||Takahata, Masahiro: 4 articles (02/2014 - 09/2011)|
|3.||Kohno, Shigeru: 3 articles (09/2014 - 12/2013)|
|4.||Mitsuyama, Junichi: 3 articles (02/2014 - 09/2011)|
|5.||Nomura, Nobuhiko: 3 articles (02/2014 - 09/2011)|
|6.||Fritsche, Thomas R: 3 articles (05/2007 - 05/2007)|
|7.||Sader, Helio S: 3 articles (05/2007 - 05/2007)|
|8.||Imai, Hirokazu: 2 articles (06/2015 - 04/2010)|
|9.||Mikamo, Hiroshige: 2 articles (06/2015 - 04/2010)|
|10.||Yamagishi, Yuka: 2 articles (06/2015 - 04/2010)|
04/01/2007 - "In addition, the tissue and fluid concentrations at 3-5 hours post-dose exceeded the minimum inhibitory concentration-90% of most targeted pathogens, suggesting that garenoxacin would be effective in the treatment of sinus, skin and skin structure, and intra-abdominal infections."
12/01/2003 - "In subsequent studies we used the neutropenic murine thigh infection model to determine if the magnitude of the AUC/MIC ratio needed for efficacy of garenoxacin varied among pathogens (including resistant strains). "
01/01/2003 - "Further study of garenoxacin is required, as it has great potential for use in the treatment of infections due to mycoplasmas and ureaplasmas."
09/01/2014 - "The efficacy rate was 4/4 for patients in whom Chlamydophila pneumoniae was detected (including 1 patient with a polymicrobial infection with another bacterial strain) and 90% (9/10 patients) for patients in whom Mycoplasma pneumoniae was detected (garenoxacin was ineffective in 1 of 2 patients with a polymicrobial infection with another bacterial strain). "
06/01/2014 - "Garenoxacin, a newer oral des-fluoroquinolone having potent antimicrobial activity against wide variety of common pathogens involved in skin and skin structure infections (SSTIs), including the resistant strains offer the advantage of broad spectrum of coverage including gram positive, gram negative and anaerobic organisms. "
|2.||Respiratory Tract Infections (Respiratory Tract Infection)
10/01/2012 - "These results suggest that garenoxacin is a highly effective and safe antimicrobial agent in the treatment of community-acquired upper respiratory infections. "
06/01/2015 - "Previous studies have suggested that garenoxacin 400 mg once daily dose is appropriate for patients with normal to moderate renal disfunction against common bacteria of respiratory infections. "
12/01/2004 - "Garenoxacin (T-3811ME, BMS-284756) is a novel, broad-spectrum des-F(6) quinolone currently under study for the treatment of community-acquired respiratory tract infections. "
05/01/2015 - "Garenoxacin a novel desfluoroquinolone appears to be an ideal antimicrobial agent for the treatment of various respiratory tract infections including CAP. "
10/01/2012 - "To determine the efficacy and safety of garenoxacin, a new generation of quinolone antimicrobial agent, in the treatment of adult upper respiratory tract infections. "
09/01/2014 - "In conclusion, garenoxacin showed an efficacy rate of greater than 90% for suspected atypical pneumonia and confirmed atypical pneumonia. "
05/01/2007 - "Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae."
03/01/2004 - "Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model."
03/01/2003 - "These data suggest that garenoxacin should be effective in the treatment of community-acquired pneumonia and chronic obstructive pulmonary disease."
05/01/2015 - "As an initial line of therapy garenoxacin was preferred in majority of cases of community-acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis. "
08/01/2007 - "Of the 9 patients with acute bacterial sinusitis due to multidrug-resistant S pneumoniae, 8 achieved clinical cure with garenoxacin treatment. "
08/01/2007 - "Limited data are available regarding the effect of garenoxacin in the treatment of acute bacterial sinusitis. "
08/01/2007 - "In this population of patients with signs and symptoms of acute maxillary sinusitis, oral garenoxacin 400 mg QD for 5 or 10 days eradicated 94% of bacterial pathogens associated with acute bacterial sinusitis in this population and appeared to be well tolerated in adults."
12/01/2004 - "Data were obtained from three phase II clinical trials of garenoxacin administered orally as 400 mg once daily for 5 to 10 days for the treatment of community-acquired pneumonia, acute exacerbation of chronic bronchitis, and sinusitis. "
10/01/2012 - "Garenoxacin (400mg/day) was administered to patients with pharyngolaryngitis, tonsillitis, and otitis media for 5-7 days and to those with sinusitis for 7-10 days. "
|5.||Renal Insufficiency (Renal Failure)
06/01/2015 - "Pharmacokinetic study of garenoxacin in severe renal failure patients."
06/01/2015 - "Consequently, for severe renal failure patients, the 400 mg once daily garenoxacin dose was expected to be effective against common bacteria of respiratory infections."
06/01/2015 - "Twenty severe renal failure patients with respiratory infection received single garenoxacin dose (200 mg and 400 mg). "
|3.||Drug Therapy (Chemotherapy)